Immunic, Inc. (NASDAQ:IMUX) Stock Has Consensus Price Target of $35.43

Immunic, Inc. (NASDAQ:IMUX) has been assigned a consensus recommendation of “Buy” from the twelve brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $35.43.

A number of research firms have issued reports on IMUX. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Immunic in a report on Thursday, September 10th. Wedbush restated an “outperform” rating and set a $45.00 price target on shares of Immunic in a report on Thursday, September 10th. Roth Capital reaffirmed a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, August 26th. Finally, LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IMUX. Braidwell LP purchased a new stake in shares of Immunic during the 2nd quarter valued at $9,914,000. Avidity Partners Management LP boosted its holdings in shares of Immunic by 42.6% in the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after buying an additional 2,000,000 shares during the last quarter. CTC Alternative Strategies Ltd. purchased a new position in shares of Immunic in the 1st quarter worth about $27,000. Bank of America Corp DE grew its position in Immunic by 80,724.2% during the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after buying an additional 143,689 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in Immunic during the first quarter valued at about $33,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $7.56 on Friday. The stock has a market cap of $103.12 million, a price-to-earnings ratio of -1.73 and a beta of 1.45. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $17.43. The firm’s 50-day simple moving average is $12.71 and its 200 day simple moving average is $12.83.

Immunic (NASDAQ:IMUX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. On average, sell-side analysts predict that Immunic will post -3.71 EPS for the current year.

About Immunic

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.